RxDoctor Payments Data

Dawn Hnat, MD

Rheumatology · Newport Beach, CANPI 1861571812

Payments from drug & device makers

$3,037in general payments, 2019–2025

Across 141 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$616
  • Amgen$483
  • AbbVie$337
  • Johnson & Johnson$260
  • Pfizer$197
  • Sanofi$171
  • plus $973 from 14 others

What the payments were for

  • Food & beverage$3,037100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,037 in reported general payments places this provider in the 50th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$53,209
Medicare patients
124
Services billed
499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnbrelEtanercept68$423,374
Enbrel SureclickEtanercept26$189,485
OrenciaAbatacept24$110,369
Cosentyx Sensoready (2 Pens)Secukinumab17$109,514
Cosentyx Sensoready PenSecukinumab12$89,637
Humira PenAdalimumab12$82,005
RinvoqUpadacitinib11$72,212
ActemraTocilizumab18$36,328
Amjevita(Cf) AutoinjectorAdalimumab-Atto23$19,331
LinzessLinaclotide13$17,825
RasuvoMethotrexate/Pf36$17,213
EliquisApixaban11$9,935
Hydroxychloroquine Sulfate165$4,772
MethotrexateMethotrexate Sodium181$4,189
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen128$3,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$483$423,37468 claims
E.r. Squibb & Sons, L.L.C.Orencia$106$110,36924 claims
AbbVieRinvoq, Linzess$337$90,03624 claims
Medexus Pharma, Inc.Rasuvo$21$17,21336 claims
PfizerEliquis$197$9,93511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 808 rheumatology providers in California.

Other rheumatology in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →